Gastrointestinal adverse events following brentuximab vedotin and polatuzumab vedotin therapy
Therapeutic Advances in Medical Oncology
Published online on February 16, 2026
Abstract
Therapeutic Advances in Medical Oncology, Volume 18, January-December 2026.
Background:Brentuximab vedotin (BV) and polatuzumab vedotin (PV), CD30-specific and CD79b-specific monoclonal antibody conjugates, respectively, are used in the treatment of hematologic cancers. Both have been observed to cause gastrointestinal adverse ...
Background:Brentuximab vedotin (BV) and polatuzumab vedotin (PV), CD30-specific and CD79b-specific monoclonal antibody conjugates, respectively, are used in the treatment of hematologic cancers. Both have been observed to cause gastrointestinal adverse ...